Senseonics Holdings Inc. is a medical technology company primarily focused on the design, development, and commercialization of long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company's flagship product, the Eversense CGM system, stands out for its innovative approach in the diabetes market, offering glucose readings that can last up to 180 days with a single sensor, significantly reducing the frequency of sensor replacements compared to traditional CGM devices. Senseonics serves the healthcare and medical device sector, impacting diabetes management practices by providing alternatives to frequent glucose testing. Headquartered in Germantown, Maryland, Senseonics Holdings Inc. collaborates with healthcare professionals and distributors worldwide to enhance the quality of life for individuals managing diabetes, contributing to advancements in healthcare technology and chronic condition monitoring. Its focus on long-term implantable solutions positions the company as a key player in ongoing efforts to improve diabetes care and patient compliance.